Skip to main content
Erschienen in: Virchows Archiv 3/2016

05.12.2015 | Original Article

Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma

verfasst von: Miguel Rito, Isabel Fonseca

Erschienen in: Virchows Archiv | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Carcinoma ex-pleomorphic adenoma (CPA) is subclassified based on the extent of penetration of the malignant component beyond the fibrous capsule of the pre-existing pleomorphic adenoma (PA). These subclasses are considered to be prognostically significant since the non-invasive/minimally invasive groups have an excellent outcome. Nevertheless, there is no consensus as to the cutoff value to distinguish between minimal and wide invasion, even though the 2005 WHO classification defines 1.5 mm as cutoff. The objective of this study is to evaluate a consecutive series of CPA, in order to establish what the effect is of the extent of extra-capsular invasion on prognosis. Fifty-eight cases of CPA were reviewed to obtain demographic and pathological information. Extent of invasion was measured. Eleven cases were non-invasive, 9 had ≤1.5 mm invasion, and for the remainder, the depth of invasion ranged between 2.5 and >10 mm. Distant metastases or death did not occur in the first two groups. In the group with ≥2.5 mm invasion, 15 patients had progressive disease and 9 of them died. The minimum extent of invasion associated with tumor progression and death was 2.5 mm. Two histologically non-invasive carcinomas had regional lymph node metastasis. CPA with ≤1.5 mm depth of invasion has good prognosis. Nevertheless, the lymph node metastases found in two cases of this group question the concept that intracapsular/minimally invasive CPA has a prognosis similar to that of PA. The minimum extent of invasion associated with death was 2.5 mm, which is at variance with findings in other recent series. Thirteen cases with depth of invasion exceeding 2.5 mm did well, confirming that additional factors should be considered in the clinical management of these patients.
Literatur
1.
Zurück zum Zitat Gnepp MSB-G DR, El-Naggar AK, Nagao T (2005) Carcinoma ex pleomorphic adenoma. In: Reichart P, Sidransky D (eds) Leon barnes JWE. Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. IARCPress, Lyon, France, pp. 242–243 Gnepp MSB-G DR, El-Naggar AK, Nagao T (2005) Carcinoma ex pleomorphic adenoma. In: Reichart P, Sidransky D (eds) Leon barnes JWE. Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. IARCPress, Lyon, France, pp. 242–243
2.
Zurück zum Zitat Gnepp DR (1993) Malignant mixed tumors of the salivary glands: a review. Pathol Annu 28:279PubMed Gnepp DR (1993) Malignant mixed tumors of the salivary glands: a review. Pathol Annu 28:279PubMed
3.
Zurück zum Zitat Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head & Neck 23(9):705–712CrossRef Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head & Neck 23(9):705–712CrossRef
4.
Zurück zum Zitat Mariano FV, Noronha AL, Gondak RO, Altemani AM, de Almeida OP, Kowalski LP (2013) Carcinoma ex pleomorphic adenoma in a Brazilian population: clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg 42(6):685–692. doi:10.1016/j.ijom.2013.02.012 CrossRefPubMed Mariano FV, Noronha AL, Gondak RO, Altemani AM, de Almeida OP, Kowalski LP (2013) Carcinoma ex pleomorphic adenoma in a Brazilian population: clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg 42(6):685–692. doi:10.​1016/​j.​ijom.​2013.​02.​012 CrossRefPubMed
5.
Zurück zum Zitat Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, Kirchner T, Ihrler S (2011) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59(4):741–750CrossRefPubMed Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, Kirchner T, Ihrler S (2011) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59(4):741–750CrossRefPubMed
6.
Zurück zum Zitat Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R (2010) Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol 41(7):927–934CrossRefPubMed Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R (2010) Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol 41(7):927–934CrossRefPubMed
8.
Zurück zum Zitat Brandwein M, Huvos AG, Dardick I, Thomas MJ, Theise ND (1996) Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontology 81(6):655–664CrossRef Brandwein M, Huvos AG, Dardick I, Thomas MJ, Theise ND (1996) Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontology 81(6):655–664CrossRef
9.
Zurück zum Zitat Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors: histomorphologic indexes. Arch Otolaryngol—Head Neck Surg 110(3):172CrossRef Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors: histomorphologic indexes. Arch Otolaryngol—Head Neck Surg 110(3):172CrossRef
10.
Zurück zum Zitat Di Palma S (2013) Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol 7(1):68–76CrossRefPubMedCentral Di Palma S (2013) Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol 7(1):68–76CrossRefPubMedCentral
11.
Zurück zum Zitat Griffith CC, Thompson LD, Assaad A, Purgina BM, Lai C, Bauman JE, Weinreb I, Seethala RR, Chiosea SI (2014) Salivary duct carcinoma and the concept of “early carcinoma ex pleomorphic adenoma”. Histopathology 65(6):854–860CrossRefPubMed Griffith CC, Thompson LD, Assaad A, Purgina BM, Lai C, Bauman JE, Weinreb I, Seethala RR, Chiosea SI (2014) Salivary duct carcinoma and the concept of “early carcinoma ex pleomorphic adenoma”. Histopathology 65(6):854–860CrossRefPubMed
12.
Zurück zum Zitat Chen MM, Roman SA, Sosa JA, Judson BL (2013) Predictors of survival in carcinoma ex pleomorphic adenoma. Head Neck 36(9):1324–1328 Chen MM, Roman SA, Sosa JA, Judson BL (2013) Predictors of survival in carcinoma ex pleomorphic adenoma. Head Neck 36(9):1324–1328
13.
Zurück zum Zitat Livolsi VA, Perzin KH (1977) Malignant mixed tumors arising in salivary glands. I Carcinomas Arising Benign Mixed Tumors: A Clinicopathologic Study Cancer 39(5):2209–2230PubMed Livolsi VA, Perzin KH (1977) Malignant mixed tumors arising in salivary glands. I Carcinomas Arising Benign Mixed Tumors: A Clinicopathologic Study Cancer 39(5):2209–2230PubMed
15.
Zurück zum Zitat Edge SB, American Joint Committee on Cancer., American Cancer Society (2010) AJCC cancer staging handbook : from the AJCC cancer staging manual, 7th edn. Springer, New YorkCrossRef Edge SB, American Joint Committee on Cancer., American Cancer Society (2010) AJCC cancer staging handbook : from the AJCC cancer staging manual, 7th edn. Springer, New YorkCrossRef
16.
Zurück zum Zitat Altemani A, Martins M, Freitas L, Soares F, Araújo N, Araújo V (2005) Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology 46(6):635–641CrossRefPubMed Altemani A, Martins M, Freitas L, Soares F, Araújo N, Araújo V (2005) Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology 46(6):635–641CrossRefPubMed
17.
Zurück zum Zitat Gerughty RM, Scofield HH, Brown FM, Hennigar GR (1969) Malignant mixed tumors of salivary gland origin. Cancer 24(3):471–486CrossRefPubMed Gerughty RM, Scofield HH, Brown FM, Hennigar GR (1969) Malignant mixed tumors of salivary gland origin. Cancer 24(3):471–486CrossRefPubMed
18.
Zurück zum Zitat Di Palma S, Skalova A, Vanieek T, Simpson R, Starek I, Leivo I (2005) Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 46(2):144–152CrossRefPubMed Di Palma S, Skalova A, Vanieek T, Simpson R, Starek I, Leivo I (2005) Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 46(2):144–152CrossRefPubMed
19.
Zurück zum Zitat Antony J, Gopalan V, Smith RA, Lam AK (2012) Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 6(1):1–9CrossRefPubMedPubMedCentral Antony J, Gopalan V, Smith RA, Lam AK (2012) Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 6(1):1–9CrossRefPubMedPubMedCentral
20.
21.
Zurück zum Zitat Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer 77(2):223–230CrossRefPubMed Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer 77(2):223–230CrossRefPubMed
22.
Zurück zum Zitat Nashed M, Casasola R (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123(02):250–252CrossRefPubMed Nashed M, Casasola R (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123(02):250–252CrossRefPubMed
23.
Zurück zum Zitat Kaidar-Person O, Billan S, Kuten A (2012) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29(2):704–706CrossRefPubMed Kaidar-Person O, Billan S, Kuten A (2012) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29(2):704–706CrossRefPubMed
24.
Zurück zum Zitat Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J, Huguet P, del Campo JM (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30(5):680–683. doi:10.1002/hed.20714 CrossRefPubMed Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J, Huguet P, del Campo JM (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30(5):680–683. doi:10.​1002/​hed.​20714 CrossRefPubMed
25.
Zurück zum Zitat Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D (2013) Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clini Cancer Res : An Off J Am Assoc Cancer Res 19(2):480–490. doi:10.1158/1078-0432.CCR-12-1842 CrossRef Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D (2013) Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clini Cancer Res : An Off J Am Assoc Cancer Res 19(2):480–490. doi:10.​1158/​1078-0432.​CCR-12-1842 CrossRef
26.
Zurück zum Zitat Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol : Off J Am Soc Clin Oncol 29(26):e727–e730. doi:10.1200/JCO.2011.36.2095 CrossRef Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol : Off J Am Soc Clin Oncol 29(26):e727–e730. doi:10.​1200/​JCO.​2011.​36.​2095 CrossRef
Metadaten
Titel
Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma
verfasst von
Miguel Rito
Isabel Fonseca
Publikationsdatum
05.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 3/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-015-1887-4

Weitere Artikel der Ausgabe 3/2016

Virchows Archiv 3/2016 Zur Ausgabe

Neu im Fachgebiet Pathologie